These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 18806728)
1. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Kuypers DR Ann Transplant; 2008; 13(3):11-8. PubMed ID: 18806728 [TBL] [Abstract][Full Text] [Related]
2. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Kuypers DR Drugs Aging; 2009; 26(9):715-37. PubMed ID: 19728747 [TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289 [TBL] [Abstract][Full Text] [Related]
5. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065 [TBL] [Abstract][Full Text] [Related]
6. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Lam S; Partovi N; Ting LS; Ensom MH Ann Pharmacother; 2008 Jul; 42(7):1037-47. PubMed ID: 18594053 [TBL] [Abstract][Full Text] [Related]
7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
8. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Brandhorst G; Tenderich G; Zittermann A; Oezpeker C; Koerfer R; Oellerich M; Armstrong VW Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473 [TBL] [Abstract][Full Text] [Related]
9. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405 [TBL] [Abstract][Full Text] [Related]
10. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Shihab F; Christians U; Smith L; Wellen JR; Kaplan B Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Holt DW Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):657-63. PubMed ID: 12394613 [TBL] [Abstract][Full Text] [Related]
12. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Oellerich M; Armstrong VW Ther Drug Monit; 2006 Dec; 28(6):720-5. PubMed ID: 17164686 [No Abstract] [Full Text] [Related]
14. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831 [TBL] [Abstract][Full Text] [Related]
15. Optimization of immunosuppressive drug monitoring in children. Filler G Transplant Proc; 2007 May; 39(4):1241-3. PubMed ID: 17524944 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients. Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599 [TBL] [Abstract][Full Text] [Related]
17. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. Rostaing L; Christiaans MH; Kovarik JM; Pascual J Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487 [TBL] [Abstract][Full Text] [Related]
19. Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. Deters M; Klabunde T; Kirchner G; Resch K; Kaever V Br J Pharmacol; 2002 Jun; 136(4):604-12. PubMed ID: 12055139 [TBL] [Abstract][Full Text] [Related]
20. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation]. Blanchet B Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]